Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

TOKYO, MUNICH& BASKING RIDGE, N.J.--(BUSINESS WIRE) December 23, 2021 --Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials